Kyverna Therapeutics Inc. (KYTX) said it signed a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis. Each participant will receive a single dose of KYV-101.
A parallel agreement will support the development of correlative studies thoroughly investigating disease biology upon KYV-101 infusion in multiple sclerosis patients, including the definition of predictors of response and the potential for immune reset.
The company noted that the investigator-initiated trial adds to the Kyverna-sponsored KYSA-7 Phase 2 study in multiple sclerosis and other sponsored KYSA trials in other rheumatological and neurological autoimmune disorders.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.